Under the guidance of our previous work, we synthesized 21 new structures of quinazolines (3a~3u)
and evaluated their in vitro anticancer activity against A549, HCT116 and MCF-7 cell lines using the MTT
method. Most compounds showed good to excellent anticancer activity. In particular, 3o (regarded as erlotinib
analogues) has marked anticancer activity against A549, HCT116 and MCF-7 cell lines (IC50s: 4.26, 3.92 and 0.14
μM, respectively) as compared with the standard anticancer drug gefitinib (IC50s: 17.9, 21.55 and 20.68 μM,
respectively), and which can be regarded as the best candidate for development of anticancer drugs.